Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Meredith

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Nature|April 1, 1982
Doves in false garbChristopher Meredith, M Hartog, J H Baumer, et al.
Gastrointestinal Endoscopy|October 24, 2006
Inferior vena cava filter eroding into duodenumBernard W K Chin, Rupert W L Leong, Andre K H Chong, et al.
American Journal of Human Genetics|August 24, 2004
Mutations in the slow skeletal muscle fiber myosin heavy chain gene (MYH7) cause laing early-onset distal myopathy (MPD1)Christopher Meredith, Ralf Herrmann, Cheryl Parry, et al.
Alimentary Pharmacology & Therapeutics|May 6, 2022
Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levelsSamuel A L Hall, Gareth S Burns, Despina Anagnostou, et al.
The Journal of Infectious Diseases|September 15, 2022
Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling PathwaysSamuel A L Hall, Gareth S Burns, Benjamin J Mooney, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 15, 2024
High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapySimon J Hume, Danny K Wong, Man-Fung Yuen, et al.
Hepatology Communications|July 17, 2023
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participantsAlexander J Thompson, Kathy Jackson, Sara Bonanzinga, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Nature|April 1, 1982
Doves in false garbChristopher Meredith, M Hartog, J H Baumer, et al.
Gastrointestinal Endoscopy|October 24, 2006
Inferior vena cava filter eroding into duodenumBernard W K Chin, Rupert W L Leong, Andre K H Chong, et al.
American Journal of Human Genetics|August 24, 2004
Mutations in the slow skeletal muscle fiber myosin heavy chain gene (MYH7) cause laing early-onset distal myopathy (MPD1)Christopher Meredith, Ralf Herrmann, Cheryl Parry, et al.
Alimentary Pharmacology & Therapeutics|May 6, 2022
Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levelsSamuel A L Hall, Gareth S Burns, Despina Anagnostou, et al.
The Journal of Infectious Diseases|September 15, 2022
Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling PathwaysSamuel A L Hall, Gareth S Burns, Benjamin J Mooney, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 15, 2024
High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapySimon J Hume, Danny K Wong, Man-Fung Yuen, et al.
Hepatology Communications|July 17, 2023
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participantsAlexander J Thompson, Kathy Jackson, Sara Bonanzinga, et al.
Pageof 1